SyntheX

SyntheX

生物技术研究

San Francisco,California 1,690 位关注者

Targeting the undruggable with synthetic biology-based drug discovery platforms

关于我们

SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner. Our lead programs focus on oncology.

网站
http://www.SyntheXlabs.com
所属行业
生物技术研究
规模
11-50 人
总部
San Francisco,California
类型
私人持股
创立
2016
领域
Oncology、Synthetic Lethality、Biotechnology、Synthetic Biology、Cancer Genetics、Therapeutics、Genetic engineering、Targeted protein degradation、Ras、Functional Selection、Drug discovery、Biologics、Peptides、Molecular glues和Raf

地点

  • 主要

    409 Illinois St

    US,California,San Francisco,94158

    获取路线

SyntheX员工

相似主页

查看职位

融资

SyntheX 共 6 轮

上一轮

未知

US$5,175,000.00

Crunchbase 上查看更多信息